SCTL - Kuehn Law Encourages FIXX SCTL EVRI and GRPH Investors to Contact Law Firm | Benzinga
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
- Homology Medicines, Inc. (NASDAQ:FIXX) click to participate
Homology Medicines has agreed to merge with Q32 Bio. Under the agreement's terms, Homology shareholders will own approximately 25% of the combined company.